IMMULITE® 2000 Anti-HBc IgM
FDA premarket approval P010053/S015 · decided 2023-08-30
Approval details
- PMA number
- P010053
- Supplement
- S015
- Supplement type
- Special (Immediate Track)
- Supplement reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Trade name
- IMMULITE® 2000 Anti-HBc IgM
- Applicant
- Siemens Healthcare Diagnostics Products, Ltd.
- Date received
- 2022-03-21
- Decision date
- 2023-08-30
- Days to decision
- 527 days
- Decision code
- APPR
- Advisory committee
- Microbiology
- Expedited review
- No
- Location
- Llanberis
- Statement
- Approval for the change in labeling to include a limitation regarding interference from the drug STRENSIQ.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.
510(k) clearances by this applicant
| Record | Firm | Date |
|---|---|---|
| IMMULITE® 2000 BR-MA (K233946) | Siemens Healthcare Diagnostics Products, Ltd. | 2024-03-13 |
| IMMULITE/IMMULITE 1000 OM-MA, IMMULITE 2000 OM-MA (K213510) | Siemens Healthcare Diagnostics Products, Ltd. | 2023-09-08 |
| IMMULITE® 2000 Cortisol (K202826) | Siemens Healthcare Diagnostics Products, Ltd. | 2021-01-15 |
| IMMULITE/IMMULITE® 1000 Cortisol (K203270) | Siemens Healthcare Diagnostics Products, Ltd. | 2021-01-15 |